Pharmaceutical manufacturing costs frequently hinge on the availability and synthesis of chiral molecules—those that, like human hands, cannot be superimposed on their mirror images. Chirality plays a crucial role in drug efficacy, metabolism, and safety profiles. The introduction of a chiral center into molecules is a notoriously complex step, often requiring multiple reaction stages, costly chiral catalysts, and laborious purification, all contributing to the soaring price tags on many medications. The novel biosynthetic process devised by the FBRI circumvents these barriers by deriving HBL directly from naturally abundant glucose, therefore creating an enantiopure compound that integrates the requisite chiral center inherently.

The research elaborates on the scalable bioconversion of glucose to (S)-HBL, highlighting an optimized catalytic protocol that enhances yield and selectivity drastically. Unlike traditional chemical methods that often employ toxic or expensive reagents to induce chirality, the team’s approach synergizes renewable feedstocks with sophisticated catalytic transformations ensuring both environmental compatibility and economic viability. By unlocking pathways to sustainable HBL production, this work addresses unmet commercial challenges while paving avenues towards greener pharmaceutical intermediate synthesis.

Glucose, the pivotal substrate in this transformative bioprocess, can be sourced sustainably from various lignocellulosic residues—byproducts of forestry and agricultural operations. This approach not only adds value to otherwise underutilized biomass waste but also anchors the production chain in renewable resources. Importantly, the process has been demonstrated to operate at high glucose concentrations, overcoming one of the key industrial hurdles related to substrate inhibition and product recovery, thereby ensuring that manufacturing remains efficient at large scales.

Beyond pharmaceutical implications, the potential horizons for this new synthetic route are expansive. (S)-HBL serves as a versatile chiral synthon, primed for the synthesis of a wide array of fine chemicals, including precursors for biodegradable plastics and specialty chemicals. The team envisions expanding feedstock profiles to include other wood sugars like xylose, a coproduct in paper processing considered waste at present. This could lead to a diversified portfolio of bio-based chemicals, including green cleaning agents and recyclable polymer precursors, fostering a circular economy rooted in renewable biomass.

Environmental benefits of the new production paradigm are equally profound. Current industrial routes for chiral building blocks predominantly rely on petrochemical feedstocks and energy-intensive synthetic chemistry, yielding significant greenhouse gas emissions. The FBRI process, by contrast, not only reduces GHG emissions drastically but also cuts production costs by over 60%, a dual advantage seldom realized in pharmaceutical manufacturing. This paves the way for more affordable medication while simultaneously mitigating environmental impacts.

Historically, attempts at sustainable HBL synthesis have grappled with myriad difficulties—be it low product titers, unsafe intermediates, or economically unfeasible pathways. Schwartz and collaborators tackled these challenges head-on by meticulously engineering reaction conditions, catalyst designs, and feedstock utilization strategies that optimize yield without compromising safety or cost-effectiveness. This marriage of chemical innovation and process engineering marks a significant milestone in green chemistry.

Integral to the success of this research was the collaborative framework involving the U.S. Department of Agriculture Forest Products Laboratory and the University of Wisconsin–Madison, NGOs recognized for their expertise in biomass science and catalysis. Contributions from UMaine graduate and undergraduate students under Schwartz’s guidance enriched the project with novel experimental insights, accelerating the translation from bench-scale reactions to industry-relevant conditions. Such interdisciplinary and cross-institutional cooperation exemplifies how tackling complex scientific problems often requires synergy across expertise domains.

The project was financially supported by leading federal bodies including the National Science Foundation, the U.S. Forest Service, and the USDA, underscoring national interest in advancing sustainable chemical manufacturing and lowering prescription drug costs. This tri-agency funding enabled state-of-the-art laboratory setups and comprehensive analytical campaigns, providing robust data backing the process claims and scalability assessments. It also reflects growing momentum in U.S. policy to leverage biomass and circular bioeconomies as pillars of sustainable industrial innovation.

Technologically, the achieved process meets multiple critical industry parameters: high yield, enantiopurity, feedstock versatility, and cost-efficiency. This aligns well with pharmaceutical industry goals to increase green chemistry adoption, improve supply chain resilience, and reduce dependency on volatile petrochemical markets. Commercial adoption of this technology could revolutionize the supply chains for essential medications, rendering statins, antibiotics, and antiviral drugs more accessible globally via a more robust, lower-cost production infrastructure rooted in renewable resources.

The researchers emphasize that their methodology is applicable beyond pharmaceuticals. Production of glycolic acid (GA), another high-demand chemical, is feasible through the same platform, presenting further economic and sustainability incentives. Such diversification potential enhances both the economic robustness and environmental sustainability of biorefinery operations, illustrating the value proposition of adopting such integrated catalytic strategies for bio-based chemical synthesis.

This research exemplifies a model for the future where scientific ingenuity intersects with environmental stewardship and economic feasibility. By coupling biomass-derived substrates with innovative synthetic strategies, it breaks down longstanding barriers hindering sustainable pharmaceutical production. The implications extend far beyond one molecule, signifying a transformative shift towards a circular bioeconomy where chemicals and materials are generated from renewable feedstocks without compromising efficiency or affordability.

As global health care systems grapple with escalating drug prices and environmental crises intensify, breakthroughs such as this illuminate pathways toward sustainable, affordable medicine. The University of Maine’s pioneering work not only charts new territory in chemical manufacturing but also sets a precedent for academia-industry-government partnerships striving to solve intertwined challenges of climate, health, and economy.

Subject of Research: Production of biorenewable, enantiopure (S)-3-hydroxy-γ-butyrolactone for pharmaceuticals

Article Title: Production of biorenewable, enantiopure (S)-3-hydroxy-γ-butyrolactone for pharmaceutical applications

News Publication Date: 18-Jul-2025

Web References:
https://www.cell.com/chem/abstract/S2451-9294(25)00256-6
http://dx.doi.org/10.1016/j.chempr.2025.102665
https://docs.nrel.gov/docs/fy04osti/35523.pdf

Image Credits: Courtesy of the University of Maine

Keywords: Biomass, Lignocellulose, Biomass production, Organic matter, Organic reactions, Catalysis, Chemical reactions, Chemical processes, Drug costs, Drug development

For decades, precious metals like platinum and rhodium have been indispensable in the synthesis processes of carbohydrate-based antibiotics. These metals facilitate complex chemical reactions, permitting the assembly of synthetic sugars necessary for the penetration and action against tenacious pathogens, including notorious culprits like Pseudomonas aeruginosa. This bacterium, prevalent in hospital settings, poses a significant threat to immunocompromised patients by resisting multiple drugs available today. However, the reliance on these metals carries significant downsides, including environmentally damaging mining practices, high production costs, and the requirement for harsh catalytic conditions that limit scalability and sustainability.

The recent publication in Nature Communications authored by an OU team led by Professor Indrajeet Sharma eye-opening overturns this paradigm by introducing a method that harnesses either blue light or iron to catalytically drive the synthesis of diazo-thioglycosides—crucial carbohydrate building blocks—without the need for traditional precious metals. By employing visible blue light as an energy source or cost-effective iron salts such as iron (III) triflate (Fe(OTf)3), these researchers achieve iterative and stereoselective glycosylations with remarkable sensitivity and selectivity. This method not only lowers the toxicological footprint of the process but also reduces operational complexities and manufacturing costs, making it highly attractive for pharmaceutical development pipelines.

The underlying chemistry capitalizes on the activation of diazo groups under blue light irradiation or iron catalysis, which facilitates the transfer of thioglycoside donors to target molecules. Unlike earlier approaches that require stringent conditions and expensive catalysts, this light-activated and iron-mediated process operates under mild and metal-sparing environments. The stereochemical control is preserved, ensuring that the resulting carbohydrate structures maintain the precise spatial orientation necessary for biological activity. This is crucial because even minute changes in carbohydrate stereochemistry can lead to profound differences in how antibiotics or pro-drugs interact with bacterial cell walls or human enzymes.

The significance of this approach extends beyond just synthetic convenience. Many antibiotics rely on carbohydrate moieties to traverse the formidable outer membrane of gram-negative bacteria—layers that traditionally obstruct drug entry, rendering several candidates ineffective. By innovating a cleaner, cheaper synthesis route, Sharma’s team potentially opens the door for designing next-generation antibiotics that use carbohydrates as molecular “keys” to breach these bacterial defenses. Such strategies could revive otherwise dormant drug candidates, enhancing their potency and broadening the scope of treatable infections amidst the accelerating global crisis of antimicrobial resistance.

A particularly fascinating facet of this research lies in its application to pro-drug development. Pro-drugs are therapeutics administered in inactive or less active forms that undergo metabolic conversion within the body to release the active compound. Carbohydrates often serve as solubility enhancers, improving a drug’s bioavailability. The OU team is investigating the attachment of specially engineered sugars, including thiosugars—sugar analogs where oxygen atoms are replaced by sulfur—using their blue light-based synthetic method. This chemical modification imparts resistance to enzymatic degradation, potentially allowing these molecules to persist longer in physiological environments and exert sustained therapeutic effects against challenging infections and even cancer.

The innovative use of blue light to drive these reactions, pioneered by lead researcher Surya Pratap Singh under Professor Sharma’s supervision, eliminates dependency on heavy metals that have plagued pharmaceutical synthesis for decades. Blue light, with wavelengths in the visible spectrum, provides a gentle yet effective energy source to activate chemical intermediates selectively without undesirable side reactions or toxicity. This metal-free activation represents a significant leap toward green chemistry principles within medicinal chemistry, reducing hazardous waste and supporting safer pharmaceutical manufacturing protocols.

Collaborations within the University of Oklahoma have further strengthened the translational potential of this work. Partnering with Professor Helen Zgurskaya, whose expertise lies in multidrug resistance mechanisms in Pseudomonas aeruginosa, the team is exploring whether their carbohydrate modifications can enhance the permeability and effectiveness of compounds developed in her lab. Many promising candidates have traditionally failed due to their inability to penetrate the bacterium’s formidable outer lipid membrane; attaching these newly synthesized carbohydrate moieties may unlock their therapeutic potential, reversing drug resistance trends.

As Professor Sharma highlights, drug-resistant infections represent a looming public health emergency expected to escalate without innovation. Synthetic carbohydrate-based antibiotics created via this blue light or iron-mediated glycosylation could be vital tools in this fight. Furthermore, the modularity and adaptability of this approach may allow rapid iteration and tailoring of drug molecules to combat emerging resistance, offering hope for dynamic drug discovery pipelines attuned to evolving microbial threats.

Beyond antibiotics, the enhanced stability and effectiveness of modified carbohydrate drugs may transform cancer treatment modalities. By prolonging drug half-lives and improving solubility, these sugar conjugates can optimize dosing regimens and minimize side effects. The inherent finesse of their synthetic strategy enables precise control over molecular architecture, a critical aspect of designing potent yet safe therapeutic agents.

This research, funded by the National Science Foundation and published in Nature Communications, demonstrates an elegant convergence of synthetic organic chemistry, photochemistry, and biomedical science. The team’s work ushers in a new era where simple, environmentally benign techniques can replace costly, toxic processes, heralding profound shifts in antibiotic and cancer drug design. By leveraging inherently abundant resources like light and iron, this innovation aligns with global sustainability goals and medical imperatives alike, potentially impacting millions of lives.

For readers interested in further details or related research, Professor Indrajeet Sharma’s laboratory website provides extensive resources and publications that delve into advanced drug discovery techniques, including this transformative blue-light-activated glycosylation method. As antibiotic resistance continues to threaten modern medicine, such creative and pragmatic solutions may prove critical in averting a post-antibiotic era.

Subject of Research: Not applicable

Article Title: Fe(OTf)3 or Photosensitizer-free blue lightactivated diazo-thioglycoside donors for Iterative and stereoselective glycosylations

News Publication Date: 21-Apr-2025

Web References:

• https://indrajeetsharma.com/
• https://ou.edu/news/articles/2025/january/how-a-single-nitrogen-atom-could-transform-the-future-of-drug-discovery
• https://www.nature.com/articles/s41467-025-56445-1

References:
Sharma, I., Singh, S.P., Chaudhary, U., Daróczi, A., & Zgurskaya, H. (2025). Fe(OTf)3 or Photosensitizer-Free Blue Light Activated Diazo-Thioglycoside Donors for Iterative and Stereoselective Glycosylations. Nature Communications, DOI: 10.1038/s41467-025-56445-1.

Image Credits: Travis Caperton

Keywords:
Antibiotic resistance, Discovery research, Drug research, Drug resistance, Drug development, Carbohydrates, Cancer treatments